Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: Analysis of the REACH study

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Garau, Javier ^a   Blasi, Francesco ^b   Medina, Jesús ^c   McBride, Kyle ^d   Ostermann, Helmut ^e  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c ASTRAZENECA   (United Kingdom)

^d Instat Consulting Inc   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Complicated skin and soft tissue infections; Early response; Epidemiology; Management; Outcomes; Resource use; Treatment failure

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CELLULITIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; EUROPEAN; FOLLICULITIS; HEALTH CARE UTILIZATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRACTICE GUIDELINE; RECURRENT INFECTION; RESOURCE MANAGEMENT; SEPTIC SHOCK; SKIN INFECTION; SKIN NECROSIS; SOFT TISSUE INFECTION; SURGICAL INFECTION; TREATMENT OUTCOME; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; EUROPE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PNEUMONIA; RETROSPECTIVE STUDY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STATISTICS AND NUMERICAL DATA; TIME; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; EUROPE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; RETROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TIME FACTORS;

EID: 84928719051     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0822-2     Document Type: Article

References (17)

1. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65 suppl 3:iii35-44.
2. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect. 2005;6:283-95.
3. Nathwani D, Moitra S, Dunbar J, Crosby G, Peterkin G, Davey P. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract. 1998;52:456-60.
4. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516-8.
5. Berger A, Oster G, Edelsberg J, Huang X, Weber DJ. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt). 2013;14:304-12.
6. Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008;29:160-9.
7. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 suppl 4:iv41-51.
8. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65 suppl 4:iv53-65.
9. US Food and Drug Administration. Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Draft Guidance. 2010.
10. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19:E377-85.
11. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2012;55:1114-21.
12. Amara S, Adamson RT, Lew I, Huang X. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI). Curr Med Res Opin. 2013;29:869-77.
13. Zervos MJ, Freeman K, Vo L, Haque N, Pokharna H, Raut M, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50:238-45.
14. Zilberberg MD, Shorr AF, Micek ST, Chen J, Ramsey AM, Hoban AP, et al. Hospitalizations with healthcare-associated complicated skin and skin structure infections: impact of inappropriate empiric therapy on outcomes. J Hosp Med. 2010;5:535-40.
15. Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012;56:2231-6.
16. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309:559-69.
17. Joo J, Yamaki J, Lou M, Hshieh S, Chu T, Shriner KA, et al. Early response assessment to guide management of methicillin-resistant Staphylococcus aureus bloodstream infections with vancomycin therapy. Clin Ther. 2013;35:995-1004.